<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04557267</url>
  </required_header>
  <id_info>
    <org_study_id>CRSU.P.SKF7F2/1019/04.08</org_study_id>
    <nct_id>NCT04557267</nct_id>
  </id_info>
  <brief_title>Dose-ranging Study of SKF7™ for Obesity</brief_title>
  <official_title>Dose-ranging Study of Labisia Pumila Aqueous Ethanolic Standardized Extract (SKF7™) for Obesity: a Randomized, Double-blind, Placebo-controlled, Phase-2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medika Natura Sdn Bhd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has been designed as a randomized, double blinded, multi-centric, placebo&#xD;
      controlled, and phase II dose-ranging study. The herbal drug contains bioactive ingredients&#xD;
      from Labisia pumila plant and it is an aqueous ethanolic standardized extract (SKF7™).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Labisia pumila or Kacip Fatimah is a native Malaysian and Indonesian plant. It has been used&#xD;
      as traditional medicine for over 400 years by both men and women for multiple treatments&#xD;
      including toning and firming the abdominal area. As a water-ethanol dry extract, it has been&#xD;
      reported to reduce body weight, cholesterol level and triglyceride level, and regulate blood&#xD;
      glucose and sex hormones. In Malaysia, this Kacip Fatimah extract has been used as a natural&#xD;
      anti-obesity drug and dietary supplement for healthy weight loss and healthy body by the&#xD;
      trade-name of Labeesity® or SKF7™. This extract has been shown to be pesticide / herbicide&#xD;
      free and has branded halal ingredient identity and security.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Actual">May 22, 2021</completion_date>
  <primary_completion_date type="Actual">May 20, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>4 parallel groups, 3 doses of study drug versus placebo</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Active drug and placebo are made in similar</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of subjects whose Body Weight is lowered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in waist and hip circumferences</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in waist and hip circumference</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the waist-hip and waist-height ratios</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in waist-hip ratio and waist-height ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Body Mass Index (BMI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in BMI in kg/m^2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body fat percentage</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change of body fat percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean Body Mass</measure>
    <time_frame>12 weeks</time_frame>
    <description>The amount of lean body mass will be calculated from body fat percentage</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of abnormal vital signs and of abnormal laboratory test results</measure>
    <time_frame>12 weeks</time_frame>
    <description>Abnormality of vital signs and laboratory test results</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>The incidence and percentage of Adverse events and serious adverse events</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Group A (dosage A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The lower dose of the active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (dosage 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The middle dose of the active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (dosage 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The higher dose of the active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low-dose</intervention_name>
    <description>Dosage 1</description>
    <arm_group_label>Group A (dosage A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Middle-dose</intervention_name>
    <description>Dosage 2</description>
    <arm_group_label>Group B (dosage 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Higher-dose</intervention_name>
    <description>Dosage 3</description>
    <arm_group_label>Group C (dosage 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group D (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men aged 18 - 50 yrs or women aged 18 until before perimenopause, with obesity&#xD;
&#xD;
          2. Willing to participate in the study by signing the informed consent&#xD;
&#xD;
          3. Healthy by anamnesis&#xD;
&#xD;
          4. Agreed to maintain their current lifestyles (no changes in their diet and physical&#xD;
             exercise) during the clinical trial period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive result for Rapid test for COVID-19 at screening period.&#xD;
&#xD;
          2. Known hypersensitivity to any herbal product.&#xD;
&#xD;
          3. Pregnant or lactating women.&#xD;
&#xD;
          4. Taking any other weight loss therapy and/or lipid lowering products.&#xD;
&#xD;
          5. Participate in other interventional clinical study or have taken other investigational&#xD;
             drug within 30 days prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arini Setiawati, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Research Supporting Unit, Faculty of Medicine, University of Indonesia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nafrialdi Agus, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharmacology &amp; Therapeutics, Faculty of Medicine, Universitas Indonesia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indonesia Medical Education and Research Institute</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine, Krida Wacana Christian University</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <zip>11510</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makara Satellite Clinic</name>
      <address>
        <city>Depok</city>
        <state>West Java</state>
        <zip>16424</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <link>
    <url>https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-used-weight-management-revision-1_en.pdf</url>
    <description>EMA Guideline on clinical evaluation of medicinal products used in weight control</description>
  </link>
  <link>
    <url>https://apps.who.int/iris/handle/10665/206936</url>
    <description>The Asia-Pacific Perspective: Redefining Obesity and its Treatment</description>
  </link>
  <results_reference>
    <citation>Lee S, Lee H, Cho Y, Kim J, Kang JW, Seo BK, Baek YH, Lee JD. The efficacy and safety of Hanslim for obese patients: Study protocol for a multicenter, randomized, double-blind, multi-dose, placebo-controlled, phase IIb clinical trial. Medicine (Baltimore). 2018 Sep;97(38):e12440. doi: 10.1097/MD.0000000000012440.</citation>
    <PMID>30235727</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 7, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Nafrialdi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>dose-ranging</keyword>
  <keyword>Kacip Fatimah</keyword>
  <keyword>Labisia pumila</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

